12:30 PM
 | 
May 15, 2018
 |  BC Extra  |  Company News

Gilead boosts foothold in cell therapy with new facilities

The Kite Pharma Inc. subsidiary of Gilead Sciences Inc. (NASDAQ:GILD) said Tuesday it has leased a new facility in Hoofddorp, the Netherlands to engineer cell therapies, including Yescarta axicabtagene ciloleucel, for patients in Europe. An MAA for...

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >